Observed versus predicted effect on cell viability and in fresh leukemic cells
. | Patient no. 1 . | . | Patient no. 2 . | . | Patient no. 3 . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Combination . | Observed . | Predicted . | Observed . | Predicted . | Observed . | Predicted . | |||
| Ida + SAHA | 58 | 44 | 73 | 48 | 73 | 72 | |||
| Ida→SAHA | 61 | 44 | 70 | 48 | 72 | 72 | |||
| SAHA→Ida | 57 | 44 | 64 | 48 | 74 | 72 | |||
. | Patient no. 1 . | . | Patient no. 2 . | . | Patient no. 3 . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Combination . | Observed . | Predicted . | Observed . | Predicted . | Observed . | Predicted . | |||
| Ida + SAHA | 58 | 44 | 73 | 48 | 73 | 72 | |||
| Ida→SAHA | 61 | 44 | 70 | 48 | 72 | 72 | |||
| SAHA→Ida | 57 | 44 | 64 | 48 | 74 | 72 | |||
Ida indicates idarubicin; SAHA, vorinostat; Ida + SAHA, concomitant administration; Ida→SAHA, idarubicin followed by vorinostat; SAHA→Ida, vorinostat followed by idarubicin.